Loading
CI
Covetrus, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by FONTEYNE PAUL R., was filed 11 Aug 2021.
Covetrus, Inc.: what insiders have been doing
This page follows insider dealings at Covetrus, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. No insider at Covetrus, Inc. has published a filing in the past twelve months. The most recent one dates from 13 October 2022.
Looking back to 2019, when coverage begins, insiders filed 4 purchases and 73 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
348
Thresholds
n/a
Buy Volume
€211,733
4 ops. · all time
Sell Volume
€16M
73 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$3.9B
Gross profitUS$738.7M19% margin
Net income-US$46.5M-1.2% margin
Last declaration on 13 October 2022
Declarations348 total
198,711 shares0Common StockSEC:0001752836-22-000150:0
28,459 shares0Common StockSEC:0001752836-22-000152:0
20,028 shares0Common StockSEC:0001752836-22-000149:0
95,406 shares0Common StockSEC:0001752836-22-000146:0
31,807 shares0Common StockSEC:0001752836-22-000140:0
15,064 shares0Common StockSEC:0001752836-22-000154:0
74,844 shares0Common StockSEC:0001752836-22-000141:0
38,095 shares0Common StockSEC:0001752836-22-000142:0
38,095 shares0Common StockSEC:0001752836-22-000155:0
23,664 shares0Common StockSEC:0001752836-22-000144:0
84,304 shares0Common StockSEC:0001752836-22-000148:0
95,079 shares0Common StockSEC:0001752836-22-000153:0
26,595 shares0Common StockSEC:0001752836-22-000151:0
13,275 shares0Common StockSEC:0001752836-22-000143:0
33,670,541 sharesCommon StockSEC:0001209191-22-053540:0
356 shares@ US$20.884.7% of flowCommon StockSEC:0001752836-22-000123:1
1,232 shares0Common StockSEC:0001752836-22-000123:0
7,631 shares@ US$20.8222.7% of flowCommon StockSEC:0001752836-22-000119:3
8,891 shares@ US$20.827.3% of flowCommon StockSEC:0001752836-22-000120:2
1,024 shares@ US$20.822.3% of flowCommon StockSEC:0001752836-22-000121:1
3,306 shares@ US$20.820.9% of flowCommon StockSEC:0001752836-22-000118:1
6,994 shares0Common StockSEC:0001752836-22-000119:1
1,643 shares0Common StockSEC:0001752836-22-000119:2
18,403 shares0Common StockSEC:0001752836-22-000120:1
7,529 shares0Common StockSEC:0001752836-22-000118:0
25 of 348 declarations
About Covetrus, Inc.
Covetrus, Inc. (ticker: CVET) is a U.S.-based animal-health company that has historically been associated with the NASDAQ market before its delisting. For French-, Belgian- and Swiss-based investors, it can be viewed as a specialized, integrated animal-health platform rather than a pure software vendor or a pure distributor. The company was created in 2019 through the combination of Henry Schein’s animal-health business and Vets First Choice, bringing together distribution capabilities, veterinary software, and digital prescription workflows under one umbrella. ([northamerica.covetrus.com](https://northamerica.covetrus.com/resource-center/blogs/news/news/2019/02/08/covetrus-celebrates-launch-as-newly-formed-public-company?utm_source=openai))
Covetrus’ business model centers on helping veterinary practices operate more efficiently and more profitably. Its offering spans practice management software, client communications tools, payment processing, prescription management, and a broad portfolio of veterinary products, consumables, medicines, equipment, and distribution services. The company serves companion animals, equine practices, and large-animal markets, which gives it exposure across multiple veterinary end-markets. In strategic terms, Covetrus sits at the intersection of software, supply chain, and animal-health commerce. ([products.covetrus.com](https://products.covetrus.com/about))
Read moreShow less
From a geographic standpoint, Covetrus is headquartered in Portland, Maine, United States, and reports operations in 19 countries worldwide. The company states that it serves more than 100,000 customers globally and employs over 5,700 people. That international footprint matters because veterinary care models and procurement patterns differ widely by geography, and Covetrus’ scale is designed to support those differences through localized distribution and software solutions. ([products.covetrus.com](https://products.covetrus.com/about))
In competitive terms, Covetrus operates in a market that is both fragmented and highly relationship-driven. Its key differentiator is the combination of technology and logistics: by linking practice software, prescription fulfillment, customer engagement, and product distribution, it aims to become embedded in daily veterinary workflows. That integrated approach can help improve customer retention, create switching costs, and support cross-selling across software and consumables. ([products.covetrus.com](https://products.covetrus.com/about))
A major recent development came in February 2026, when Covetrus announced a definitive agreement with Cencora to merge Covetrus and MWI Animal Health into a combined animal-health platform. Management framed the transaction as a way to broaden access to products and solutions, strengthen logistics, and improve affordability and accessibility across the animal-health ecosystem. For equity investors, this is an important strategic signal: Covetrus remains a consolidation candidate and a key asset in the ongoing restructuring of the U.S. animal-health distribution and technology landscape. ([s203.q4cdn.com](https://s203.q4cdn.com/785768684/files/doc_news/Covetrus-and-MWI-Animal-Health-to-Merge-2026.pdf))
